Our industry’s first Drug Preparation Premises (DPP) facility will allow TerrAscend the ability to innovate and produce specialized pharmaceutical products for healthcare professionals and institutions. Solace Rx will deliver formulations that will address unmet medical needs where no commercial product is otherwise available.

Solace Rx further positions TerrAscend as a leading medical cannabis company in the field of personalized medicine. Operations of Solace Rx are scheduled to launch in 2019. For more information, contact Mike Hannalah, President & Co-Founder, at info@solacerx.com.